By the end of the year Advent is scheduled to attain commercial manufacturing certification. This will include the production for DCVax-L once it is approved by RAs. It is reasonable to assume RA approval for DCVax-L will be close to manufacturing certification even if a BLA/MAA has not yet been submitted as the approval process is often times shorter for an accelerated approval than it takes to grant commercial manufacturing certification.
I agree with this Ex! DCVax-L RA approval(s) are incoming! Have a good one my friend. by.
Cell therapy companies even with phenomenal results often take much, much longer to file their application for marketing approval. Your information is it really very good.